The U.S.-China Trade Blockade
Across 1 sector, 3 filers are signaling falling regulatory exposure. Accelerated into 2025Q4, since cooling. Reached 3 sectors at its 2025Q4 peak, now concentrated in 1 sector. Primarily a risk story (63%), with a regulatory overlay (38%). Forward-leaning — companies are guiding to this, not just explaining the past. One disclosure notes "challenged due to tariffs, export restrictions and related supply chain constraints."
Aerospace and pharmaceutical manufacturers face present and future operational constraints from U.S.-China tariffs, sanctions, and export restrictions that directly threaten deliveries and supply chains.
DISTINCT NEW FILERS PER QUARTER
✦ WHAT THE DIFF CAUGHT
Language shifts from regulatory documentation of current trade barriers to forward-looking risk of delivery disruption, indicating operational urgency has moved beyond compliance disclosure.
REPRESENTATIVE SIGNAL FROM FILINGS
“challenged due to tariffs, export restrictions and related supply chain constraints”
Tariffs, export restrictions, and supply chain constraints are constraining the U.S.-China trade relationship.
“lead to trade retaliation, including through the use of counter tariffs, foreign exchange measures or large-scale sale of U.S. Treasury bonds”
U.S.-China trade escalation could trigger trade retaliation including counter tariffs, foreign exchange measures, and large-scale Treasury bond sales.
DRIVERS